PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29578577-2	2018	Posaconazole (POS), a substrate of glucuronosyltransferase and P-glycoprotein, and voriconazole (VRC), a substrate of CYP2C9/19, are commonly administered to transplant recipients.	posaconazole	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	63-77	
31741622-1	2019	The aim of this study was to determine the impact of ABCB1 polymorphism, BMI, age and drug co-administration on safety and efficiency of posaconazole (PCZ) oral suspension treatment in children with hematological diseases.	posaconazole	137-149	ATP binding cassette subfamily B member 1	Homo sapiens	53-58	
31741622-1	2019	The aim of this study was to determine the impact of ABCB1 polymorphism, BMI, age and drug co-administration on safety and efficiency of posaconazole (PCZ) oral suspension treatment in children with hematological diseases.	posaconazole	151-154	ATP binding cassette subfamily B member 1	Homo sapiens	53-58	
30259783-0	2019	Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein.	posaconazole	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	69-83	
30259783-2	2019	Posaconazole is not extensively metabolized by these isozymes but is both a p-glycoprotein (P-gp) substrate and inhibitor.	posaconazole	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	76-90	
30259783-2	2019	Posaconazole is not extensively metabolized by these isozymes but is both a p-glycoprotein (P-gp) substrate and inhibitor.	posaconazole	0-12	ATP binding cassette subfamily B member 1	Homo sapiens	92-96	
32472569-3	2021	PCZ is an inhibitor of cytochrome P450 3A4 and P-glycoprotein.	posaconazole	0-3	ATP binding cassette subfamily B member 1	Homo sapiens	47-61	
29578577-2	2018	Posaconazole (POS), a substrate of glucuronosyltransferase and P-glycoprotein, and voriconazole (VRC), a substrate of CYP2C9/19, are commonly administered to transplant recipients.	posaconazole	14-17	ATP binding cassette subfamily B member 1	Homo sapiens	63-77	
27530244-5	2017	We speculate that posaconazole may inhibit the cytarabine efflux through P-glycoprotein inhibition leading to the patient"s palmar-plantar erythrodysesthesia and subsequent aplasia.	posaconazole	18-30	ATP binding cassette subfamily B member 1	Homo sapiens	73-87	
27510521-10	2016	CONCLUSIONS: Voriconazole, and to a minor extent posaconazole, increase plasma exposure to sublingual buprenorphine, probably via inhibition of cytochrome P450 3 A and/or P-glycoprotein.	posaconazole	49-61	ATP binding cassette subfamily B member 1	Homo sapiens	171-185	
27001813-4	2016	Fifty percent inhibitory concentrations (IC50s) for P-gp and BCRP were both 2 muM for itraconazole, 5 and 12 muM for hydroxyitraconazole, 3 and 6 muM for posaconazole, and 3 and 11 muM for isavuconazole, respectively.	posaconazole	154-166	ATP binding cassette subfamily B member 1	Homo sapiens	52-56	
21420575-8	2011	Moreover, itraconazole and posaconazole are substrates and inhibitors of the transporter protein, P-glycoprotein.	posaconazole	27-39	ATP binding cassette subfamily B member 1	Homo sapiens	98-112